No. 15-1195
Vide 15-1039

Title:	Amgen Inc., et al., Petitioners v. Sandoz Inc.
Docketed:	March 23, 2016
Lower Ct:	United States Court of Appeals for the Federal Circuit
Case Nos.:	(2015-1499)
Decision Date:	July 21, 2015
Rehearing Denied:	October 16, 2015

Questions Presented

~~Date~~~	~~~~~~~Proceedings and Orders~~~~~~~~~~~~~~~~~~~~
Mar 21 2016	Petition for a writ of certiorari filed. (Response due April 22, 2016)
Apr 18 2016	Order extending time to file response to petition to and including May 17, 2016.
May 17 2016	Brief of respondent Sandoz Inc. in opposition filed.
May 27 2016	Reply of petitioners Amgen Inc., et al. filed.
May 31 2016	DISTRIBUTED for Conference of June 16, 2016.
Jun 20 2016	The Solicitor General is invited to file a brief in this case expressing the views of the United States.
Dec 7 2016	Brief amicus curiae of United States filed. VIDED.
Dec 20 2016	Supplemental brief of petitioners Amgen Inc., et al. filed. VIDED.
Dec 21 2016	DISTRIBUTED for Conference of January 6, 2017.
Jan 9 2017	DISTRIBUTED for Conference of January 13, 2017.
Jan 13 2017	Petition GRANTED. The petition for a writ of certiorari in No. 15-1039 is granted. The cases are consolidated and a total of one hour is allotted for oral argument.
Jan 25 2017	The following briefing schedule is adopted: Petitioner in No. 15-1039 will file an opening brief limited to the question presented in its petition, not to exceed 15,000 words, on or before Friday, February 10, 2017. Petitioners in No. 15-1195 will file a consolidated opening brief on the question presented in their petition and response brief, not to exceed 19,000 words, on or before Friday, March 10, 2017. Petitioner in No. 15-1039 will file a consolidated response brief and reply brief, not to exceed 10,000 words, on or before Friday, March 31, 2017. Petitioners in No. 15-1195 will file a reply brief, not to exceed 6,000 words, on or before Friday, April 14, 2017. Any brief of an amicus curiae in support of petitioner in No. 15-1039 or in support of neither party is to be filed on or before Friday, February 17, 2017, and the brief should bear a light green cover. Any brief of an amicus curiae in support of petitioners in No. 15-1195 is to be filed on or before Friday, March 17, 2017, and the brief should bear a dark green cover. An amicus curiae may file only a single brief in these cases. VIDED.
Jan 30 2017	Joint motion of the parties to dispense with printing the joint appendix filed. VIDED.
Feb 17 2017	SET FOR ARGUMENT ON Wednesday, April 26, 2017. VIDED.
Feb 17 2017	Brief amici curiae of Apotex Inc. and Apotex Corp. filed. VIDED.
Feb 17 2017	Brief amicus curiae of Coherus Biosciences, Inc. filed. VIDED.
Feb 17 2017	Brief amicus curiae of America's Insurance Health Plans filed. VIDED.
Feb 17 2017	Brief amicus curiae of United States filed. VIDED.

Feb 17 2017	Brief amicus curiae of Biosimilars Council filed. VIDED.
Feb 17 2017	Brief amicus curiae of Mylan Inc. filed. VIDED.
Feb 21 2017	Motion to dispense with printing the joint appendix filed by petitioners GRANTED. VIDED.
Feb 24 2017	Record requested from the U.S.C.A. for the Federal Circuit. VIDED.
Mar 10 2017	Opening and Response Brief for Amgen Inc., et al. filed. VIDED.
Mar 17 2017	Brief amicus curiae of AbbVie Inc. filed. VIDED.
Mar 17 2017	Motion of the Acting Solicitor General for leave to participate in oral argument as amicus curiae and for divided argument filed. VIDED.
Mar 17 2017	Brief amici curiae of Eleven Professors filed.
Mar 17 2017	Brief amicus curiae of Janssen Biotech, Inc. filed. VIDED.
Mar 17 2017	Brief amicus curiae of Biotechnology Innovation Organization. filed. VIDED.
Mar 17 2017	Brief amicus curiae of Genentech, Inc. filed. VIDED.
Mar 22 2017	CIRCULATED.
Mar 27 2017	Record received from the U.S.C.A. for the Federal Circuit. The record is available on PACER, except for confidential materials transmitted separately. VIDED.
Mar 31 2017	Consolidated Response and Reply Brief of Sandoz Inc. filed. VIDED. (Distributed)
Apr 13 2017	Motion of the Acting Solicitor General for leave to participate in oral argument as amici curiae and for divided argument GRANTED. VIDED. Justice Gorsuch too no part in the consideration or decision of this motion.
Apr 13 2017	Reply of petitioners Amgen Inc., et al. filed. (Distributed)
Apr 26 2017	Argued. For petitioner in No. 15-1039: Deanne E. Maynard, Washington, D. C.; and Anthony A. Yang, Assistant to the Solicitor General, Department of Justice, Washington, D. C. (for United States, as amicus curiae.) For petitioners in 15-1195: Seth P. Waxman, Washington, D. C. VIDED.
Jun 12 2017	Adjudged to be VACATED IN PART, REVERSED IN PART, and case REMANDED. Thomas, J., delivered the opinion for a unanimous Court. Breyer, J., filed a concurring opinion. VIDED.
Jul 14 2017	JUDGMENT ISSUED.

~~Name~~~~~~~~~~~~~~~~~~~~~~	~~~~~~~Address~~~~~~~~~~~~~~~~~~	~~Phone~~~
Attorneys for Petitioners:		
Seth P. Waxman Counsel of Record	Wilmer Cutler Pickering Hale and Dorr LLP 1875 Pennsylvania Avenue, N.W. Washington, DC 20006 seth.waxman@wilmerhale.com	(202) 663-6000
Party name: Amgen Inc., et al.		
Nicholas Groombridge	Paul, Weiss, Rifkind, Wharton & Garrison, LLP 1285 Avenue of the Americas New York, NY 10019-6064 ngroombridge@paulweiss.com	(212) 373-3000
Party name: Amgen Inc., et al.		
Attorneys for Respondent:		
Deanne E. Maynard Counsel of Record	Morrison & Foerster LLP 2000 Pennsylvania Avenue, N.W. Washington, DC 20006 DMaynard@mofo.com	(202) 887-8740
Party name: Sandoz Inc.		

Other:

Carlos T. Angulo	Zuckerman Spaeder LLP 1800 M St., N.W., Suite 100 Washington, DC 20036 cangulo@zuckerman.com	(202) 778-1800

Party name: America's Insurance Health Plans.

Craig E. Countryman	Fish & Richardson, P.C. 12390 El Camino Real San Diego, CA 92130 countryman@fr.com	(858) 678-5070

Party name: Coherus Biosciences, Inc.

Gregory L. Diskant	Patterson Belknap Webb & Tyler LLP 1133 Avenue of the Americas New York, NY 10036 gldiskant@pbwt.com	(212) 336-2000

Party name: Janssen Biotech, Inc.

David C. Frederick	Kellogg, Hansen, Todd, Figel & Frederick, P.L.L.C. 1615 M Street, N.W., Suite 400 Washington, DC 20036 dfrederick@kellogghansen.com	(202) 326-7900

Party name: Apotex Inc. and Apotex Corp.

William M. Jay	Goodwin Procter LLP 901 New York Avenue, N.W. Washington, DC 20001 wjay@goodwinlaw.com	(202) 346-4000

Party name: Biosimilars Council

Kevin E. Noonan	McDonnell Boehnen Hulbert & Berghoff, LLP 300 South Wacker Drive Chicago, IL 60606 noonan@mbhb.com	(312) 913-0001

Party name: Eleven Professors

William A. Rakoczy	Rakoczy Molino Mazzochi Siwik LLP 6 West Hubbard Street, Suite 500 Chicago, IL 60654 wrakoczy@rmmslegal.com	(312) 527-2157

Party name: Mylan Inc.

E. Joshua Rosenkranz	Orrick, Herrington & Sutcliffe LLP 51 West 52nd Street	(212) 506-5380

	New York, NY 10019-6142 jrosenkranz@orrick.com	
Party name: Genentech, Inc.		
Melissa Arbus Sherry	Latham & Watkins LLP 555 Eleventh Street, NW Suite 1000 Washington, DC 20004 melissa.sherry@lw.com	(202) 637-2200
Party name: AbbVie Inc..		
Jeffrey B. Wall	Acting Solicitor General United States Department of Justice 950 Pennsylvania Avenue, N.W. Washington, DC 20530-0001 SupremeCtBriefs@USDOJ.gov	(202) 514-2217
Party name: United States		
Donald R. Ware	Foley Hoag LLP 155 Seaport Boulevard Boston, MA 02210 drw@foleyhoag.com	(617) 832-1000
Party name: Biotechnology Innovation Organization		
Anthony Alan Yang	Office of the Solicitor General 950 Pennsylvania Ave. NW Room 5615 Washington, DC 20530-0001	(202) 514-4821
Party name: United States		